A Food and Drug Administration advisory panel approved of broad distribution of the Pfizer COVID-19 vaccine, the Wall Street Journal reports.
Pfizer and Biotech said in a statement that they hope to see their vaccine be potentially available by mid-to-late December.
Pfizer and BioNTech have developed and recently tested BNT162b2—a COVID-19 vaccine which has been found to be over 95 percent successful in preventing the virus through multiple trials.
In a July 22 press release, Pfizer announced "the execution of an agreement with the US Department of Health and Human Services and the Department of Defense."
Join our mailing list to receive a daily email with all of our top stories